Oregovomab not checked
CanariaBio Inc. · MAb-B43.13 · Monoclonal antibody B43.13
FollowEvery change as it happens, and a Monday email
Trials
4 active
4 in total · 1 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes”In the company’s words, NCT04498117 on ClinicalTrials.gov
- Tested for
- Ovarian Cancer (2 trials), Ovarian Serous Adenocarcinoma (2 trials), Fallopian Tube Neoplasms (2 trials), Peritoneal Cancer (2 trials), Peritoneal Carcinoma (2 trials), Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Adenocarcinoma and 12 more
- Main trialPhase 3
- “Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.”In the company’s words, NCT04498117 on ClinicalTrials.gov
- Other names
- MAb-B43.13 · Monoclonal antibody B43.13
Other drugs for Ovarian Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab SoravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
- AxitinibPfizer · Phase 3
Coming up3
- 26 DecPhase 3 trial completes · ClinicalTrials.gov
- 30 DecPhase 2 trial completes · ClinicalTrials.gov
- 15 May 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 26 Dec 2026 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | |
| Phase 2Active, not recruiting | 30 Dec 2026 | A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | |
| Phase 2Active, not recruiting | 15 May 2027 | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | |
| Phase 1/2Active, not recruiting | 30 Oct 2025 | Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026